截至2025年6月24日,A股及港股市场多家上市公司陆续发布公告。以下为我们梳理的公司公告摘要。1.医疗科技来凯医药(2105.HK)在2025年美国糖尿病协会(ADA)年会上公布其三款抗体药(LAE102、LAE103、LAE123)的研究进展。其中LAE102在I期临床中表现出良好耐受性与稳定药代动力学,LAE123则为双靶点抗体,显示在增肌减脂方面的潜力。药物仍处临床前与早期阶段,未来仍具...
Source Link截至2025年6月24日,A股及港股市场多家上市公司陆续发布公告。以下为我们梳理的公司公告摘要。1.医疗科技来凯医药(2105.HK)在2025年美国糖尿病协会(ADA)年会上公布其三款抗体药(LAE102、LAE103、LAE123)的研究进展。其中LAE102在I期临床中表现出良好耐受性与稳定药代动力学,LAE123则为双靶点抗体,显示在增肌减脂方面的潜力。药物仍处临床前与早期阶段,未来仍具...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.